Trial Profile
A retrospective study to evaluate to safety and efficacy of Sunitinib in patients with metastatic renal cell carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacokinetics; Therapeutic Use
- 28 Nov 2015 New trial record